Karl E. Anderson, MD is a graduate of the Johns Hopkins University School of Medicine. He completed his residency training in internal medicine and postgraduate training in gastroenterology at Vanderbilt University Hospital and New York Hospital Cornell Medical Center. Prior to joining the University of Texas Medical Branch in 1987, Dr. Anderson held faculty appointments at the Rockefeller University, Cornell University Medical College, and New York Medical College. He is currently a Professor in the Departments of Preventive Medicine and Community Health and Internal Medicine within the Division of Gastroenterology and Hepatology. He is also a member of the Institute for Translational Sciences and the Academy of Research Mentors. Dr. Anderson serves as Director of the Clinical Science Program in the Graduate School of Biomedical Sciences and is an active clinical investigator on the Institute for Translational Sciences Clinical Research Center, where he also holds the role of Associate Director. His research program is supported by the NIH, FDA, foundations, and industry partners. Internationally recognized for his work in the human porphyrias, Dr. Anderson's research and clinical expertise focus on the diagnosis, pathophysiology, and treatment of porphyria disorders, including acute intermittent porphyria. Through his leadership in translational research and clinical investigation, he has played a pivotal role in advancing evidence based therapies and improving care for patients with rare metabolic and hematologic conditions.

Catherine Broome, MD is a Professor of Medicine in the Division of Hematology/Oncology at MedStar Georgetown University Hospital in Washington, DC. She is board-certified in internal medicine, hematology, and medical oncology. Catherine Broome, MD has been on staff at the Georgetown Lombardi Comprehensive Cancer Center for over a decade, where she specializes in benign hematology. Her clinical expertise encompasses a range of hematologic disorders, including immune thrombocytopenia (ITP), autoimmune hemolytic anemia, cold agglutinin disease, hemophagocytic lymphohistiocytosis, paroxysmal nocturnal hemoglobinuria (PNH), and pure red cell aplasia. Catherine Broome, MD is actively involved in clinical research and offers patients the opportunity to participate in clinical trials for various hematologic conditions. In addition to her clinical work, Catherine Broome, MD serves as an associate professor in the Department of Medicine at Georgetown University, contributing to the education and training of future physicians. She also participates in the hospital's safety committee, focusing on developing programs and policies to ensure patient safety throughout MedStar Health. Catherine Broome, MD's approach to patient care emphasizes collaboration, providing patients with the most up-to-date information and treatment options, and developing personalized treatment plans that consider all aspects of the patient's life.

Susan O'Brien, MD is a Professor of Medicine in the Division of Hematology/Oncology at the University of California, Irvine, where she previously served as Associate Director for Clinical Science at the Chao Family Comprehensive Cancer Center. She earned her medical degree at the University of Medicine and Dentistry of New Jersey and completed her fellowship in Hematology/Oncology at MD Anderson Cancer Center, where she later held the Ashbel Smith Professorship of Medicine. Internationally recognized for her expertise in leukemia, Susan O'Brien, MD has been instrumental in developing novel therapies for both acute and chronic forms of the disease, with a particular focus on chronic lymphocytic leukemia (CLL). She was a leading investigator in the early clinical trials of ibrutinib (Imbruvica), a groundbreaking therapy for CLL, and has served as principal investigator on numerous clinical studies. Susan O'Brien, MD has authored more than 900 peer-reviewed publications, making her one of the most highly cited researchers in the field of leukemia. She also serves in leadership roles with cooperative oncology groups and contributes to patient advocacy through her work with organizations such as the CLL Society. Her achievements have been recognized with multiple honors, including the Giant of Cancer Care Award in Leukemia, the Binet–Rai Medal for innovation in CLL research, and the Excellence in Scientific Service Award from the Leukemia & Lymphoma Society.